High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC

High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC

Introduction Despite significant successes, immune checkpoint blockade fails to achieve clinical responses in a significant proportion of patients, predictive markers for responses are imperfect and immune-related adverse events (irAEs) are unpredictable. We used T-cell receptor (TCR) sequencing to...

Full description

Saved in:
Bibliographic Details
Main Authors: Alexandre Reuben, Mehmet Altan, Latasha Little, Jianjun Zhang, Ajay Sheshadri, Hai T Tran, Mara B Antonoff, Stephen G Swisher, John V Heymach, Saumil Gandhi, Natalie Vokes, Ziyi Li, Ruoxing Li, Runzhe Chen, Joshua Baguley, Jefferson Sinson, Greg Lizee
Format: Article
Language:English
Published: BMJ Publishing Group 2024-12-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/12/e008950.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/12/12/e008950.full

Similar Items